Bioequivalence studies are crucial assessments in the field of pharmaceutical research, serving to establish the comparable efficacy and safety profiles of generic and reference drugs. These studies explore the extent and rate at which the active ingredients in different formulations are absorbed, allowing researchers to determine if generic alternatives can be substituted for their brand-name counterparts.
Conducted through meticulous trials and statistical analyses, bioequivalence studies contribute significantly to regulatory decision-making processes. By ensuring that generic medications are bioequivalent to their branded versions, these studies play a pivotal role in the approval and availability of cost-effective alternatives, promoting accessibility to essential medications.
As a cornerstone in the pharmaceutical industry, bioequivalence studies exemplify the commitment to both innovation and affordability, fostering a landscape where patients can confidently rely on generic options without compromising therapeutic outcomes or safety. The meticulous pursuit of equivalence in drug formulations underscores the dedication to advancing healthcare by balancing efficacy, safety, and accessibility.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia